Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

NanoString Technologies Inc (NASDAQ:NSTG)

Delayed Data
As of Dec 11
 -0.01 / -0.13%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

NanoString Technologies, Inc. provides life science tools for translational research and molecular diagnostic products. It specializes in the development, manufacture, and sale of biologic information from minute amounts of tissue. It offers nCounter Analysis System which directly profiles hundreds of molecules simultaneously using a novel barcoding technology to researchers in academic, government, and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of disease and to clinical laboratories and medical centers for diagnostic use. It also provides Prosigna Breast Cancer Assay which is a molecular diagnostic product that provides an assessment of a patient's risk of recurrence for breast cancer. The company was founded by Amber Ratcliffe, Krassen Dimitrov, and Dwayne Dunaway on June 20, 2003 and is headquartered in Seattle, WA.

Contact Information

NanoString Technologies, Inc.
530 Fairview Avenue North
Seattle Washington 98109
P:(888) 358-6266
Investor Relations:
(206) 602-1768



Other institutional52.56%
Individual stakeholders26.33%
Mutual fund holders26.09%

Top Executives

Robert Bradley GrayPresident, Chief Executive Officer & Director
Mary Tedd AllenSenior Vice President-Operations
James Algot JohnsonCFO & Principal Accounting Officer
Alessandra CesanoChief Medical Officer
Kathryn Surace-SmithSecretary, Vice President & General Counsel